Clinical Trial Outcomes with Monotherapy The REDEFINE 1 trial demonstrated that cagrilintide monotherapy at the 4.5 mg maintenance dose produced mean body weight reductions of approximately 10.8% from baseline after 32 weeks of treatment [4]
If approved, your weekly injections can typically begin at your next in-clinic visit
We are committed to providing the highest quality research materials and the information you need to use them correctly
population of African American descent, 8 of the top 10 alleles for U.S
(2) Tavares AB, Micmacher E, Biesek S, Assumpo R, Redorat R, Veloso U, Vaisman M, Farinatti PT, Conceio F
Letrozole ionizes in both positive and negative ionization modes, while anastrozole undergoes only positive ionization